The invention is directed to a urea plant with a high pressure synthesis section and a recovery section. The high pressure synthesis section comprises a reactor, a stripper and a condenser, wherein the reactor operates at a higher pressure than the stripper and the condenser. The plant further includes a compression unit between the condenser and the reactor. The compression unit utilizes mechanical energy recovered from a decompression unit positioned downstream of the stripper and upstream of the recovery section.

Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.

Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.

Disclosed is a novel method of controlling the formation of biuret in urea production, and particularly reducing, preventing or reversing such formation. This is accomplished by adding liquid ammonia to a urea aqueous stream. This addition is done at one or more positions downstream of a recovery section in a urea plant. The addition of liquid ammonia serves to shift the equilibrium of biuret formation from urea, to the side of the formation of urea from biuret and ammonia. The invention can be accomplished also in pre-existing urea plant, by the simple measure of providing an appropriate inlet for liquid ammonia, in fluid communication with a source of such liquid ammonia.

Disclosed is a urea plant wherein, in deviation from conventional plants, a high-pressure synthesis section is operated with two different pressures. The synthesis section comprises a reactor, which is operated under a first high pressure. The synthesis section also comprises a stripper and a condenser, both operated at substantially the same second high pressure. In accordance with the invention, the first pressure is substantially higher than the second pressure. The disclosed plant particularly comprises a compression unit capable of converting a pressure difference into work, or more specifically, mechanical energy for compression. This compression unit is positioned between a liquid outlet of the condenser and a liquid inlet of the reactor, and in fluid communication therewith. In order to make use of a pressure drop (expansion as a result of a liquid being depressurized), said compression unit is configured to obtain compression energy from one or more events in the urea production process (i.e., at one or more points in the urea production plant), at which a loss of energy occurs, such as decompression of a high energy stream. Typically, the compression unit is thereby configured to utilize mechanical energy recovered from a decompression unit positioned downstream of the stripper and upstream of the recovery section.

Disclosed is a urea plant wherein, in deviation from conventional plants, a high-pressure synthesis section is operated with two different pressures. The synthesis section comprises a reactor, which is operated under a first high pressure. The synthesis section also comprises a stripper and a condenser, both operated at substantially the same second high pressure. In accordance with the invention, the first pressure is substantially higher than the second pressure. The disclosed plant particularly comprises a compression unit capable of converting a pressure difference into work, or more specifically, mechanical energy for compression. This compression unit is positioned between a liquid outlet of the condenser and a liquid inlet of the reactor, and in fluid communication therewith. In order to make use of a pressure drop (expansion as a result of a liquid being depressurized), said compression unit is configured to obtain compression energy from one or more events in the urea production process (i.e., at one or more points in the urea production plant), at which a loss of energy occurs, such as decompression of a high energy stream. Typically, the compression unit is thereby configured to utilize mechanical energy recovered from a decompression unit positioned downstream of the stripper and upstream of the recovery section.

New tranilast complexes and new tranilast cocrystals are disclosed. These include a 1:1 tranilast nicotinamide complex, a 1:1 tranilast nicotinamide cocrystal, a 1:1 tranilast saccharin complex, a 1:1 tranilast saccharin cocrystal, a 1:1 tranilast gentisic acid complex, a 1:1 tranilast gentisic acid cocrystal, a 1:1 tranilast salicylic acid complex, a 1:1 tranilast salicylic acid cocrystal, a 1:1 tranilast urea complex, a 1:1 tranilast urea cocrystal, a 1:1 tranilast 4-aminobenzoic acid complex, a 1:1 tranilast 4-aminobenzoic acid cocrystal, a 1:1 tranilast 2,4-dihydroxybenzoic acid complex and a 1:1 tranilast 2,4-dihydroxybenzoic acid cocrystal. Also disclosed are pharmaceutical compositions containing a tranilast complex or cocrystal of the invention and a pharmaceutically acceptable carrier. Methods of treatment using the tranilast complexes and cocrystals as well as the pharmaceutical compositions are disclosed.

New tranilast complexes and new tranilast cocrystals are disclosed. These include a 1:1 tranilast nicotinamide complex, a 1:1 tranilast nicotinamide cocrystal, a 1:1 tranilast saccharin complex, a 1:1 tranilast saccharin cocrystal, a 1:1 tranilast gentisic acid complex, a 1:1 tranilast gentisic acid cocrystal, a 1:1 tranilast salicylic acid complex, a 1:1 tranilast salicylic acid cocrystal, a 1:1 tranilast urea complex, a 1:1 tranilast urea cocrystal, a 1:1 tranilast 4-aminobenzoic acid complex, a 1:1 tranilast 4-aminobenzoic acid cocrystal, a 1:1 tranilast 2,4-dihydroxybenzoic acid complex and a 1:1 tranilast 2,4-dihydroxybenzoic acid cocrystal. Also disclosed are pharmaceutical compositions containing a tranilast complex or cocrystal of the invention and a pharmaceutically acceptable carrier. Methods of treatment using the tranilast complexes and cocrystals as well as the pharmaceutical compositions are disclosed.

The invention relates to novel crystalline forms of 3-(4-amino-l-oxo-l,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione, including a novel urea cocrystal of 3-(4-amino-l-oxo-l,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel gallic acid cocrystal of 3-(4-amino-l-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel propyl gallate cocrystal of 3-(4-amino-l-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; and a novel L-tartaric acid cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention are described. The invention also relates to pharmaceutical compositions containing the novel crystalline forms, and the therapeutic use of the novel crystalline forms.

The invention relates to novel crystalline forms of 3-(4-amino-l-oxo-l,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione, including a novel urea cocrystal of 3-(4-amino-l-oxo-l,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel gallic acid cocrystal of 3-(4-amino-l-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; a novel propyl gallate cocrystal of 3-(4-amino-l-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione; and a novel L-tartaric acid cocrystal of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention are described. The invention also relates to pharmaceutical compositions containing the novel crystalline forms, and the therapeutic use of the novel crystalline forms.